Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Am Heart J. 2011 Feb;161(2):397-403.e1. doi: 10.1016/j.ahj.2010.11.004.
Patients with diabetes mellitus (DM) are at higher risk for adverse outcomes following percutaneous coronary intervention (PCI).
To determine whether outcomes have improved over time, we analyzed data from 2,838 consecutive patients with medically treated DM, including 1,066 patients (37.6%) treated with insulin, in the National Heart, Lung, and Blood Institute Dynamic Registry undergoing PCI registered in waves 1 (1997-1998), 2 (1999), 3 (2001-2002), 4 (2004), and 5 (2006). We compared baseline demographics and 1-year outcomes in the overall cohort and in analyses stratified by recruitment wave and insulin use.
Crude mortality rates by chronological wave were 9.5%, 12.5%, 8.9%, 11.6%, and 6.6% (P value(trend) = .33) among those treated with insulin and, respectively, 9.7%, 6.5%, 4.1%, 5.4%, and 4.7% (P value(trend) = .006) among patients treated with oral agents,. The adjusted hazard ratios of death, myocardial infarction (MI), and overall major adverse cardiovascular events (death, MI, revascularization) in insulin-treated patients with DM in waves 2 to 5 as compared with wave 1 were either higher or the same. In contrast, the similar adjusted hazard ratios for oral agent-treated patients with DM were either similar or lower.
Significant improvements over time in adverse events by 1 year were detected in patients with DM treated with oral agents. In insulin-treated diabetic patients, despite lower rates of repeat revascularization over time, death and MI following PCI have not significantly improved. These findings underscore the need for continued efforts at optimizing outcomes among patients with DM undergoing PCI, especially those requiring insulin treatment.
患有糖尿病(DM)的患者在经皮冠状动脉介入治疗(PCI)后发生不良结局的风险较高。
为了确定随着时间的推移结果是否有所改善,我们分析了来自国家心肺血液研究所动态注册处 2838 例接受药物治疗的 DM 连续患者的数据,其中包括在波 1(1997-1998 年)、波 2(1999 年)、波 3(2001-2002 年)、波 4(2004 年)和波 5(2006 年)期间接受 PCI 治疗的 1066 例(37.6%)胰岛素治疗的患者。我们比较了总体队列以及按招募波和胰岛素使用分层分析的基线人口统计学和 1 年结局。
按时间顺序波,胰岛素治疗患者的死亡率分别为 9.5%、12.5%、8.9%、11.6%和 6.6%(趋势 P 值=.33),而口服药物治疗患者分别为 9.7%、6.5%、4.1%、5.4%和 4.7%(趋势 P 值=.006)。与波 1 相比,波 2 至 5 中接受胰岛素治疗的 DM 患者死亡、心肌梗死(MI)和总体主要不良心血管事件(死亡、MI、血运重建)的调整后的危险比更高或相同。相比之下,接受口服药物治疗的 DM 患者的相似调整后的危险比相似或更低。
在接受口服药物治疗的 DM 患者中,1 年内不良事件的时间显著改善。在接受胰岛素治疗的糖尿病患者中,尽管随着时间的推移,再次血运重建的比率降低,但 PCI 后死亡和 MI 并未显著改善。这些发现强调需要继续努力优化接受 PCI 的 DM 患者的结局,特别是那些需要胰岛素治疗的患者。